Filing Flows › Gyre Therapeutics (GYRE) › Q1 2026
Gyre Therapeutics (GYRE) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 8, 2026
Gyre Therapeutics (GYRE) reported revenue of $22.5M for the first quarter 2026 (Q1 2026), +2% from a year earlier and -39% from the quarter before. Operating margin was -41.5%, net loss $9.9M (43.8% of revenue).
Gyre Therapeutics, Q1 2026: revenue $22.5M (+2% year over year), operating margin -41.5%, net loss $9.9M, operating cash flow $3.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $22.5M | -39% | +2% |
| Operating profit | −$9.4M | -8028% | -512% |
| Net earnings | −$9.9M | — | -364% |
| Operating cash flow | $3.2M | — | — |
| Free cash flow | $3.0M | — | — |
What changed
Revenue was $22.5M in Q1 2026, up 2% year over year and down 39% from the previous quarter.
Operating costs exceeded revenue by $9.4M, an operating margin of -41.5%. The fastest-growing cost line was Research & development (+118%). The quarter ended with a net loss of $9.9M, wider than the previous quarter's $1.4M loss.
Operating cash flow was $3.2M. Non-cash charges added back $672K of depreciation and amortization and $2.6M of share-based compensation. Working capital and other items added $9.8M. Capital expenditures of $178K left free cash flow of $3.0M.
Questions
What was Gyre Therapeutics' revenue in the first quarter 2026?
Gyre Therapeutics (GYRE) reported revenue of $22.5M for the first quarter 2026 (Q1 2026), +2% from a year earlier and -39% from the quarter before.
Was Gyre Therapeutics profitable in the first quarter 2026?
Operating loss was $9.4M (-41.5% of revenue) and net loss $9.9M.
Source: Gyre Therapeutics 10-Q on SEC EDGAR.